CA9 and acute myeloid leukemia: Our screening of three different, dual CA IX/XII inhibitors showed dose dependent activity against a panel of primary FLT3/ITD+ AML cells from ND and R/R samples, irrespective of the O2 concentration used in the in vitro setting.